Showing 110 of 100 policies89 effective·0 urgent·1 upcoming·7 future
Page 1 / 10
CommercialPrior AuthMedium aetna.com
Effective Mar 14, 2025· Identified Aug 12, 2026
Codes
J92759641396415C44.02C44.121C44.1292C44.221C44.229C44.320C44.329C44.42C44.520C44.529C44.621C44.629C44.721C44.729C44.82C44.92

Cosibelimab-ipdl (Unloxcyt) (CPB 1074, reviewed 2026-03-25)

Aetna·Medical Policy·National, Dermatology, Oncology, General Surgery

Aetna has established a new medical policy for cosibelimab-ipdl (Unloxcyt), a PD-L1 blocking antibody approved for metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients not candidates for curative surgery or radiation. The policy requires precertification for all commercial plans, specifies approved billing codes (J9275, 96413, 96415), and limits coverage to CSCC only—all other indications are considered experimental. Billing teams must implement prior authorization requirements and ensure proper diagnosis coding before claims submission.

Action Required
Before March 14, 2025: (1) Billing team must update systems to require precertification for all HCPCS code J9275 (cosibelimab-ipdl) claims on Aetna commercial plans. (2) Establish precertification process: contact (866) 752-7021 or fax (888) 267-3277 with Statement of Medical Necessity forms before claim submission. (3) Update diagnosis coding rules to allow only ICD-10 codes C44.02 through C44.92 (cutaneous squamous cell carcinoma) for coverage; flag claims with other diagnoses for manual review and denial. (4) Add site-of-care review requirement per Aetna's Utilization Management Policy on specialty drug infusions. (5) Providers must document that patient is not a candidate for curative surgery or radiation in medical record before treatment. (6) Train front-desk staff to initiate precertification requests at scheduling; educate providers that claims without prior authorization will be denied. Failure to implement precertification will result in claim denials.
Open policy
CommercialCoverageMedium aetna.com
Effective Mar 25, 2026· Identified Aug 12, 2026
Codes
J1642J1643J1644S9336Z79.01

Conversion of Anti-Coagulants to Heparin Before and After Elective Surgery (CPB 0200, reviewed 2026-03-25)

Aetna·Surgery·National, Cardiology, Cardiothoracic Surgery, General Surgery, Vascular Surgery, Critical Care, Internal Medicine

Aetna's CPB 0200 policy (effective 2026-03-25) establishes medical necessity criteria for continuous intravenous heparin infusion when converting anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin) before and after elective surgery. The policy allows up to 3 inpatient pre-procedure days when anti-coagulation must be maintained due to thrombotic risk. Billing teams must ensure proper coding and documentation for heparin infusion services and related anticoagulant monitoring.

Action Required
By 2026-03-25: Billing team must implement the following: (1) Update billing system to recognize J1642, J1643, J1644 (heparin injection codes) and S9336 (home infusion therapy code) as covered when criteria are met for anticoagulant conversion cases; (2) Ensure Z79.01 (long-term anticoagulant use) is documented on all claims involving heparin bridging therapy; (3) Require providers to document medical necessity for inpatient pre-procedure days (up to 3 days allowed) when anti-coagulation maintenance is clinically indicated—include risk assessment for thromboembolism vs. bleeding; (4) Train billing staff that pre-procedure weaning may be done outpatient in most cases, but inpatient admission is covered only when circumstances compromise anti-coagulation state; (5) Flag claims for audit if more than 3 inpatient pre-procedure days are billed; (6) Coordinate with clinical teams to ensure providers document which anticoagulant is being converted (apixaban, dabigatran, edoxaban, rivaroxaban, or warfarin) and the clinical justification for heparin bridging. Failure to obtain proper medical necessity documentation will result in claim denials.
Open policy
All PlansCoverageHigh aetna.com
Effective Jun 25, 2026· Identified Aug 12, 2026

Cosmetic Surgery and Procedures (CPB 0031, reviewed 2026-06-25)

Aetna·Surgery·National, Plastic Surgery, General Surgery, ENT (Ear, Nose & Throat), Dermatology, Ophthalmology, Urology, OB-GYN

Aetna updated its Clinical Policy Bulletin 0031 on cosmetic surgery coverage (effective 2026-06-25). The policy clarifies which procedures are covered as medically necessary versus excluded as cosmetic, including specific criteria for procedures like blepharoplasty, breast reduction, rhinoplasty, and gender-affirming surgeries. Billing teams must verify medical necessity documentation and apply the detailed inclusion/exclusion criteria to prevent claim denials for cosmetic procedures.

Action Required
By 2026-06-25: Billing and authorization teams must implement the following changes: (1) Update pre-authorization workflows to require physicians to submit medical necessity documentation (photographs, clinical letters, chart records) for all procedures listed in CPB 0031 Section 'Medical Necessity Surgeries and Procedures' before claim submission. (2) Configure billing system to automatically flag and deny claims for procedures listed under the 'Cosmetic' section (e.g., labiaplasty, cheek implants, buttock lift, breast augmentation for non-gender-dysphoria cases) unless prior authorization explicitly overrides with medical necessity justification. (3) Create a reference guide for front-desk and authorization staff listing 35+ procedures with their medical necessity criteria and required documentation. (4) For procedures with conditional coverage (e.g., earlobe repair only for traumatic injury, not pierced-hole closure), train billing staff to verify procedure indication in clinical notes before processing. (5) Update claim denial templates to cite the specific cosmetic exclusion from CPB 0031. Providers must submit appeals with medical necessity documentation if they dispute cosmetic classification. Failure to implement will result in improper claim payments for non-covered cosmetic procedures and potential recovery audits from Aetna.
Open policy
CommercialPrior AuthMedium aetna.com
Effective Dec 9, 2025· Identified Aug 12, 2026
Codes
96365J0791D57.00D57.01D57.02D57.1D57.20D57.211D57.212D57.219D57.3D57.40D57.41D57.411D57.412D57.419D57.42D57.43D57.44D57.45D57.46D57.80D57.81D57.811D57.812D57.819

Crizanlizumab-tmca (Adakveo) (CPB 0964, reviewed 2025-12-09)

Aetna·Medical Policy·National, Hematology, Internal Medicine, Pediatrics

Aetna has issued a fresh medical policy (CPB 0964, effective 2025-12-09) establishing coverage criteria for crizanlizumab-tmca (Adakveo), a P-selectin monoclonal antibody for reducing vaso-occlusive crises in sickle cell disease patients aged 16+. The policy mandates precertification for all commercial plans, requires hematologist/sickle cell specialist prescription, and establishes specific clinical criteria including prior VOC history and either alternative genotypes or hydroxyurea failure/contraindication/concurrent use.

Action Required
By December 9, 2025: Billing team must implement the following: (1) Update billing system to require MANDATORY precertification for all Adakveo (J0791) claims before submission—route precertification requests to Aetna at (866) 752-7021 or fax (888) 267-3277; (2) Configure system to validate that prescriber is a hematologist or sickle cell disease specialist before processing claims; (3) Build clinical validation rules requiring documentation of: member age ≥16 years, at least one VOC in prior 12 months, AND either (a) non-HbSS/HbSβ0 genotype OR (b) HbSS/HbSβ0 genotype with prior hydroxyurea inadequacy/intolerance/contraindication or concurrent hydroxyurea use; (4) Link CPT 96365 (infusion administration) to J0791 to prevent billing infusion code without drug code; (5) Add continuation of therapy validation requiring documented VOC reduction since initiation to support renewal authorizations; (6) Update provider communications to clarify that Site of Care utilization management policy applies and specify infusion site requirements per separate UM policy. Claims lacking precertification or failing to meet clinical criteria will be denied. Providers must complete Statement of Medical Necessity (SMN) forms available through Specialty Pharmacy Precertification portal.
Open policy
CommercialCoverageMedium aetna.com
Effective Jan 27, 2026· Identified Aug 12, 2026
Codes
9093590999J0889D63.1

Daprodustat (Jesduvroq) (CPB 1044, reviewed 2026-01-27)

Aetna·Medical Policy·National, Nephrology, Critical Care

Aetna has established new coverage criteria for daprodustat (Jesduvroq), an oral medication for anemia in dialysis patients with CKD. The policy requires: (1) patients must have received dialysis for at least 4 months with pretreatment hemoglobin ≤11 g/dL for initial approval, (2) adequate iron stores (TSAT ≥20%) or concurrent iron therapy, and (3) no concurrent use with ESAs. All other indications are considered experimental. This is the first time Aetna has formally established coverage for this newly FDA-approved medication (February 2023).

Action Required
By February 27, 2026: Billing team must implement the following: (1) Update billing system to recognize HCPCS code J0889 (daprodustat oral 1 mg) for ESRD dialysis patients only; (2) Configure system to require documentation of: patient on dialysis ≥4 months, pretreatment hemoglobin ≤11 g/dL (initial approval) or current hemoglobin <12 g/dL (continuation), serum TSAT ≥20% within 3 months, and confirmation of no concurrent ESA use; (3) Add prior authorization requirement to claim submission workflow for all J0889 claims; (4) Update encounter templates for nephrology providers to capture required qualifying criteria at point of service; (5) Train billing staff to deny claims that lack evidence of iron sufficiency assessment or show concurrent ESA billing. Failure to implement these controls will result in claim denials and recoupment for non-compliant submissions.
Open policy
CommercialPrior AuthMedium aetna.com
Effective Mar 27, 2026· Identified Aug 12, 2026
Codes
J1307D59.59640196402964139641496415

Crovalimab-akkz (PiaSky) (CPB 1064, reviewed 2026-03-27)

Aetna·Medical Policy·National, Hematology, Internal Medicine, Critical Care, Infectious Disease

Aetna has established a new medical policy (CPB 1064, effective 2026-03-27) for crovalimab-akkz (PiaSky), a complement C5 inhibitor for treating paroxysmal nocturnal hemoglobinuria (PNH) in patients 13+ years old weighing ≥40 kg. The policy requires precertification, strict diagnostic criteria including GPI-AP deficiency confirmation via flow cytometry, clinical disease manifestations, and prohibits concurrent use with other complement inhibitors. Continuation of therapy requires documentation of positive response and absence of unacceptable toxicity.

Action Required
By 2026-03-27: (1) Billing team must implement mandatory precertification requirement for all crovalimab-akkz (PiaSky) claims—contact Aetna at (866) 752-7021 or fax (888) 267-3277 before claim submission; (2) Update billing system to enforce precertification flag for HCPCS code J1307; (3) Create documentation checklist requiring providers to document: patient age ≥13 years, body weight ≥40 kg, confirmed PNH diagnosis with GPI-AP deficiency ≥5% via flow cytometry, clinical disease manifestations (LDH >1.5 ULN, thrombosis, renal dysfunction, pulmonary hypertension, or dysphagia), and confirmation of no concurrent complement inhibitor use (Empaveli, Fabhalta, Soliris, Ultomiris); (4) For reauthorization claims, require documentation of positive response (improved hemoglobin, normalized LDH) and no unacceptable toxicity; (5) Providers must complete Statement of Medical Necessity (SMN) precertification forms per Specialty Pharmacy Precertification process; (6) Review Site of Care Utilization Management Policy to ensure appropriate site selection for specialty drug infusions; (7) Update encounter forms and billing templates to reflect new diagnostic and clinical requirement documentation. Claims submitted without completed precertification or missing required medical necessity documentation will be denied.
Open policy
CommercialCoverageMedium aetna.com
Effective Dec 15, 2025· Identified Aug 12, 2026
Codes
906119062286580875939046090461904719047290749A50.01A63.8Z20.2Z20.89Z23Z72.51Z72.52Z72.53

Orthopoxvirus Vaccines (CPB 0644, reviewed 2025-12-15)

Aetna·Medical Policy·National, Allergy & Immunology, Infectious Disease, Occupational Medicine, Family Medicine, Internal Medicine, General Practice, Pediatrics

Aetna updated its orthopoxvirus vaccine policy (CPB 0644) effective 2025-12-15, establishing medical necessity criteria for smallpox and mpox vaccinations. The policy covers pre-exposure vaccination for high-risk groups (laboratory workers, healthcare workers, public health personnel), post-exposure vaccination for exposed individuals, and mpox vaccination for persons with specific risk factors. Billing teams must ensure proper CPT code selection (90611, 90622) and ICD-10 diagnosis codes are used based on the patient's risk category and vaccination indication.

Action Required
By 2025-12-15: Billing team must update claim submission protocols to require proper documentation of medical necessity for orthopoxvirus vaccines. (1) For CPT 90611 (JYNNEOS vaccine) and CPT 90622 (ACAM2000 vaccine): Verify patient meets one of Aetna's covered indications before processing claims. (2) Link appropriate ICD-10 diagnosis codes: Use Z23 for pre-exposure smallpox vaccination, Z20.2 or Z20.89 for exposure scenarios, and Z72.51/Z72.52/Z72.53 for mpox risk factors. (3) Update billing system to flag claims lacking proper risk category documentation and route to providers for completion. (4) Train front-desk and billing staff that smallpox/mpox vaccination for general population (without documented risk factors) is non-covered per this policy. (5) Note: Verify individual plan documents as most plans exclude work/travel-required vaccinations. Failure to document medical necessity will result in claim denials.
Open policy
CommercialCoverageHigh aetna.com
Effective Jan 20, 2026· Identified Aug 12, 2026

Orthopedic Casts, Braces and Splints (CPB 0009, reviewed 2026-01-20)

Aetna·DME·National, Orthopedics, Podiatry, Pediatrics, Physical Therapy, General Surgery, PM&R (Physical Medicine & Rehab)

Aetna has updated its comprehensive policy on orthopedic casts, braces, and splints (CPB 0009) effective January 20, 2026. The policy clarifies medical necessity criteria, provider qualifications, and coverage distinctions (DME vs. surgical protocol) for various orthotic devices including back braces, cast-braces, cervical collars, and specialized pediatric braces. Key requirements include prescriber qualifications, provider certification (ABC or BOC), 6-month prescription window, and documented improvement in mobility-related activities of daily living (MRADLs).

Action Required
By January 20, 2026: Billing team must implement the following changes: (1) Verify all orthotic device claims include prescriber credentials (physician, NP, podiatrist, or qualified health professional per state law) before processing; (2) Confirm provider certification status with American Board for Certification (ABC), Board of Certification/Accreditation (BOC), or state licensure documentation on file prior to claim submission; (3) Update claim scrubbing rules to reject cast-braces and back braces without evidence of prescription within 6 months of device provision; (4) Flag post-operative back braces (must be applied within 6 weeks post-surgery) separately from DME back braces in billing system; (5) Implement requirement that custom-fitted back braces must show prior failure/contraindication/intolerance to off-the-shelf braces or post-operative use, or claims will be denied; (6) Educate providers that cervical foam neck collars are non-covered (not durable) and should not be billed; (7) For pediatric hip braces and scoliosis braces, ensure documentation demonstrates stabilization/correction of congenital defect or medical necessity. Claims lacking proper documentation of prescriber qualifications, provider certification, or medical necessity criteria will face denial or recoupment.
Open policy
CommercialPrior AuthHigh aetna.com
Effective Mar 18, 2026· Identified Aug 12, 2026
Codes
210832108421085210882114121142211432114521146

Orthognathic Surgery (CPB 0095, reviewed 2026-03-18)

Aetna·Surgery·National, Oral & Maxillofacial Surgery, Dentistry, Plastic Surgery

Aetna has issued a comprehensive clinical policy bulletin (CPB 0095) for orthognathic surgery that defines medical necessity criteria, documentation requirements, and coverage exclusions. The policy requires precertification before orthognathic surgery and clearly delineates covered skeletal deformities (masticatory dysfunction, airway defects, speech impairment with cleft) versus non-covered cosmetic procedures. Billing teams must implement precertification workflows and ensure orthognathic surgery is approved BEFORE any pre-surgical orthodontic treatment begins.

Action Required
REQUIREMENTS: - Immediately (upon implementation): Billing and precertification teams must establish a mandatory precertification workflow for ALL orthognathic surgery cases (CPT 21083, 21084, 21085, 21088, 21141, 21142, 21143, 21145, 21146). Route all precertification requests to Aetna's Oral and Maxillofacial Surgery Unit. - Before any orthognathic surgery claim is processed: Verify that precertification was obtained BEFORE pre-surgical orthodontic treatment was initiated. Deny claims if precertification approval predates orthodontic care start date. - Update all patient eligibility verification forms and provider scheduling systems to flag orthognathic cases for mandatory precertification before any treatment begins. - Provide providers with documentation checklist (skeletal deformity study models, pre-orthodontic imaging, detailed functional impairment description) to include with precertification requests. - Reject and deny any orthognathic surgery claims performed for cosmetic purposes (including isolated mentoplasty/chin surgeries for genial hypoplasia, hypertrophy, or asymmetry). - Implement billing rules to separate orthodontic treatment costs (pre- and post-surgical) as dental benefits—do NOT process under medical claims. - Flag and deny any claims for experimental/investigational procedures: condylar positioning devices, low-level laser therapy for post-op management, manual lymphatic drainage, non-biodegradable osteosynthesis, 3D virtual treatment planning (CASNOS), or Kinesio taping. - CONSEQUENCE: Failure to obtain precertification before orthodontic care or failure to verify precertification will result in claim denial per policy language.
Open policy
CommercialCoverageHigh aetna.com
Effective Dec 24, 2025· Identified Aug 12, 2026
Codes
57120572805728257288574255726757284572858140081479A4556A4557A4558A4595C1781E0720E0730G0283S8948K62.2K62.3N81.0N81.9N39.41N39.498N95.2R10.2R10.24R32R39.81

Organ Prolapse: Selected Procedures (CPB 0858, reviewed 2025-12-24)

Aetna·Medical Policy·National, OB-GYN, General Surgery

Aetna's updated Organ Prolapse policy (CPB 0858, effective 2025-12-24) establishes medical necessity coverage for five specific procedures including laparoscopic suture rectopexy, sacrocolpopexy, and tension-free vaginal tape surgery, while classifying ten additional procedures and technologies as experimental/investigational. Billing teams must update systems to deny claims for non-covered experimental procedures and ensure prior authorization documentation aligns with the five covered interventions.

Action Required
By 2025-12-24: Billing team must update billing software to flag and deny claims for experimental procedures (biodegradable cog threads, biologic grafts, laser therapy, pectopexy, TENS therapy, vNOTES procedures, vaginal tactile imaging, genetic testing for prolapse). Verify that only CPT codes 57120, 57280, 57282, 57288, 57425 process as covered when paired with ICD-10 codes K62.2, K62.3, N81.0-N81.9. Implement system edits to reject CPT 0487T, 0552T, 57267/57284/57285 with biologic grafts, HCPCS A4556-A4595, C1781, E0720, E0730, G0283, S8948, and genetic testing codes (81400-81479) for organ prolapse indications. Update encounter templates to require documentation of medical necessity for covered procedures. Inform providers that claims for experimental procedures will be denied. Flag ICD-10 codes N39.41-N39.498, N95.2, R10.2-R10.24, R32, R39.81 as non-covered for this policy.
Open policy
110 of 100 · Page 1 / 10
Policy Assistant